ChemicalBook > Product Catalog >API >Synthetic Anti-infective Drugs >Quinolones >Lomefloxacin

Lomefloxacin

Lomefloxacin Suppliers list
Company Name: Capot Chemical Co.,Ltd.
Tel: +86 (0)571-855 867 18
Email: sales@capotchem.com
Products Intro: Product Name:Lomefloxacin
CAS:98079-51-7
Purity:98%(Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Email: info@dakenchem.com
Products Intro: Product Name:Lomefloxacin
CAS:98079-51-7
Purity:99.00% Package:100g,500g,1KG,10KG,100KG
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: CAS:98079-51-7
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: Mainchem Co., Ltd.
Tel: +86-0592-6210733
Email: sales@mainchem.com
Products Intro: Product Name:Lomefloxacin
CAS:98079-51-7
Company Name: PI & PI BIOTECH INC.
Tel: 020-81716320
Email: Sales@pipitech.com
Products Intro: Product Name:Lomefloxacin
CAS:98079-51-7
Purity:90%+ Package:10mg, 25mg, 50mg, 100mg, Other scale please email Sales@pipitech.com Remarks:1-Ethyl-6,8-difluoro-7-(3-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinoline Carboxylic Acid

Lastest Price from Lomefloxacin manufacturers

  • Lomefloxacin
  • US $1.00 / KG
  • 2019-09-02
  • CAS:98079-51-7
  • Min. Order: 1KG
  • Purity: ≥98%
  • Supply Ability: 200KG
Lomefloxacin Basic information
Description References
Product Name:Lomefloxacin
Synonyms:LEMOFLOXACIN;LOMEFLOXACIN;LOMEFLOXACIN BASE;1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid;1,4-dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolin;1-Ethyl-6,8-difluoro-7-(3-methylpiperazino)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;LFLX;LoMenfloxacin
CAS:98079-51-7
MF:C17H19F2N3O3
MW:351.35
EINECS:619-317-6
Product Categories:Active Pharmaceutical Ingredients;Antibiotic Explorer;-;Peptide Synthesis/Antibiotics
Mol File:98079-51-7.mol
Lomefloxacin Structure
Lomefloxacin Chemical Properties
Melting point 239-240 C
storage temp. −20°C
CAS DataBase Reference98079-51-7(CAS DataBase Reference)
Safety Information
Hazard Codes Xn,Xi
Risk Statements 22-36/37/38
Safety Statements 26-36
WGK Germany 3
RTECS VB1997500
HS Code 29419000
ToxicityLD50 in mice (mg/kg): 245.6 i.v.; >4000 orally (Itoh)
Lomefloxacin Usage And Synthesis
DescriptionLomefloxacin is a kind of fluoroquinolone antibiotics used for the treatment of bacterial infections such as bronchitis and urinary tract infection. It can also used to prevent the urinary tract infections prior surgery. It has bactericidal effect against a wide range of gram-negative and gram-positive organisms. It takes effect through interfering with the normal function of the bacteria enzyme DNA gyrase and topoisomerase IV, further inhibiting the transcription and replication of bacterial DNA. This effect results in strand breakage of bacterial chromosome, supercoiling and resealing, further causing bacteria death.
Referenceshttps://en.wikipedia.org/wiki/Lomefloxacin
https://www.drugbank.ca/drugs/DB00978
DescriptionLomefloxacin is a once-daily, third-generation quinolone antibiotic useful in the treatment of bacterial infections. The new fluorinated quinolone does not interfere with the metabolism of theophylline; it is efficacious against pathogens resistant to cephalosporins, penicillins and aminoglycosides.
Chemical Propertiescolorless Needles
OriginatorHokuriku Seiyaku (Japan)
UsesAnti bacterial.
DefinitionChEBI: A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.
Brand nameUniquin
Pharmaceutical ApplicationsA difluoropiperazinyl quinolone formulated as the hydrochloride salt for oral administration. The in-vitro activity is very similar to that of norfloxacin . It is active against Enterobacteriaceae and fastidious Gram-negative bacilli, including L. pneumophila. Activity against Campylobacter spp., Ps. aeruginosa, Acinetobacter and Chlamydia spp. is poor. It has reduced activity against staphylococci and poor activity against streptococci, L. monocytogenes, anaerobes and Mycobacterium spp.
A 400 mg oral dose achieves a concentration of 3–5 mg/L after 1–1.5 h. In escalating oral doses of 100, 400 and 800 mg to volunteers, the AUC was essentially proportional to the dosage, the mean plasma concentrations following 100, 400 and 800 mg doses being approximately 1.1, 4.7 and 7.5 mg/L, respectively.
Several metabolites have been described, accounting for <5% of the oral dose. Elimination occurs principally via the kidneys and 50–70% of a dose appears in the urine over 24 h. In patients with impaired renal function given 400 mg orally, the apparent elimination half-life ranged from 8 to 44 h, depending on the degree of renal failure. Non-renal clearance was also impaired, but there was no significant change in other pharmacokinetic parameters. The daily dosage (400 mg) should be reduced to 280 mg when the creatinine clearance falls below 30 mL/min. Hemodialysis has no effect on the plasma concentration. The effect of lomefloxacin on the plasma concentration of theophylline is clinically insignificant and no dosage adjustment is required.
The main adverse event is phototoxicity; other adverse events (mainly diarrhea, abdominal pain, skin reactions, dizziness, headache and insomnia) occur in about 10% of patients.
It is chiefly used in urinary tract infection, but is no longer widely available.
Clinical Use1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid (Maxaquin) is adifluorinated quinolone with a longer elimination half-life(7–8 hours) than other members of its class. It is the onlyquinolone for which once-daily oral dosing suffices. The oralbioavailability of lomefloxacin is estimated to be 95% to98%. Food slows, but does not prevent, its oral absorption.The extent of biotransformation of lomefloxacin is only about5%, and high concentrations of unchanged drug, rangingfrom 60% to 80%, are excreted in the urine. The comparativelylong half-life of lomefloxacin is apparently because ofits excellent tissue distribution and renal reabsorption and not because of plasma protein binding (only ~10%) or enterohepaticrecycling (biliary excretion is estimated to be ~10%).
Lomefloxacin has been approved for two primary indications. First, it is indicated for acute bacterial exacerbations of chronic bronchitis caused by H. influenzae or Moraxella (Branhamella) catarrhalis, but not if Streptococcus pneumoniae is the causative organism. Second, it is used for prophylaxis of infection following transurethral surgery. Lomefloxacin also finds application in the treatment of acute cystitis and chronic urinary tract infections caused by Gram-negative bacilli.
Tag:Lomefloxacin(98079-51-7) Related Product Information
Methyl Kresoxim-methyl Methanol LOMEFLOXACIN HCL,LOMEFLOXACIN HYDROCHLORIDE 1-Methylpiperazine 2-Butanone 2,6-Dimethyl-7-octen-2-ol N-Aminoethylpiperazine (2-Methoxyethyl)benzene Sparfloxacin SPARFLOXACIN, [2-14C]- Sparfloxacin Orbifloxacin AKOS NCG1-0016 LOMEFLOXACIN, ASPARTATE ORBIFLOXACIN Lomefloxacin Methylparaben